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Background: The human body plays host to a vast array of bacteria, found in oral cavities, skin, gastrointestinal
tract and the vagina. Some bacteria are harmful while others are beneficial to the host. Despite the availability of
many methods to identify bacteria, most of them are only applicable to specific and cultivable bacteria and are also
tedious. Based on high throughput sequencing technology, this work derives 16S rRNA sequences of bacteria and
analyzes probiotics and pathogens species.
Results: We constructed a database that recorded the species of probiotics and pathogens from literature, along
with a modified Smith-Waterman algorithm for assigning the taxonomy of the sequenced 16S rRNA sequences. We
also constructed a bacteria disease risk model for seven diseases based on 98 samples. Applicability of the proposed
platform is demonstrated by collecting the microbiome in human gut of 13 samples.
Conclusions: The proposed platform provides a relatively easy means of identifying a certain amount of bacteria
and their species (including uncultivable pathogens) for clinical microbiology applications. That is, detecting how
probiotics and pathogens inhabit humans and how affect their health can significantly contribute to develop a
diagnosis and treatment method.Background
High throughput sequencing can analyze a large amount
of sequences, enabling sequencing of 16S rRNA to identify
complex bacteria species of pathogens and probiotic bac-
teria. Many naturally occurring bacteria form a complex
population in the environment. The human body plays
host to a vast array of bacteria, found in oral cavities, skin,
gastrointestinal tract and the vagina. Some bacteria are
harmful while others are beneficial to the host.
A pathogen is a microorganism that causes disease in its
host. For example, bacterial pathogen include Corynebacter-
ium diphtheria (causes diphtheria), Listeria monocytogenes* Correspondence: a4467@ms7.mmh.org.tw; bryan@mail.nctu.edu.tw
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reproduction in any medium, provided the or(causes food poisons), and Legionella pneumophila (causes
Legionnaires’ disease). Probiotics, another microorganism,
benefit the host and has received considerable attention in
recent years. A FAO report in 2001 [1] cited the advan-
tages of probiotics as increasing immunity [2,3], reducing
gastrointestinal discomfort [4,5], and protecting the flora
within urogenital tract [6]. As is well known, probiotics
can ameliorate symptoms of diseases [7] and reduce the
risk of suffering from diseases [8,9].
Despite the availability of many approaches to identify
probiotics and pathogens, most of them are only applic-
able to specific and cultivable bacteria but time consum-
ing. For instance, conventional methods detect growth
of cultured bacteria in approximately two days, or an
additional five days to obtain no-growth culture results
[10], which is laborious. Besides, some bacteria cannot
be cultured [11], subsequently increasing the difficulty of
specifying pathogenic bacteria. Moreover, it is hard tod. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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more bacteria types.
16S rRNA sequences, capable of identifying bacteria
on a molecular level, can detect uncultivable bacteria
[12]. Use of 16S rRNA sequencing can overcome some
problems of conventional culture method [13]. Although
16S rRNA sequencing is a more effective means of
identifying bacteria than conventional culture method,
16S rRNA sequencing takes a considerable amount of
time in amplifying DNA sequences [14]. Sanger sequen-
cing known as “first-generation” or “conventional” sequen-
cing has been used for DNA sequencing for almost two
decades. Next generation sequencing (NGS) can analyze
large-scale sequences quicker, enable massively parallel
analysis, reduce reagent costs and the size of sample com-
ponents, and perform high throughput [15]. Thus NGS is
more efficient than the Sanger method, which generates
one read per sample. In addition, NGS of 16S rRNA more
easily identify cultivable or uncultivable bacteria [12].
Because of the improvement of sequencing technology
and Bioinformatics approaches, the accuracy in distin-
guishing bacteria with those methods has been increased.
Based on high throughput sequencing technology, this
work identifies 16S rRNA sequences of bacteria and ana-
lyzes bacteria species. High-throughput sequencing can
sequence a large number of 16S rRNA sequence more
efficiently; with high-throughput sequencing, researchers
can acquire information to identify pathogens and
probiotic bacteria [16-18].
Results
Platform application: gut probiotics and pathogens
detection
The read statistics of quality filtering and taxonomy
assignment are demonstrated in Table 1. Figure 1ATable 1 Results of quality filtering and taxonomy assignment
ID Raw reads QC Bacteria
B011 125420 117451 93.65% 90952
B012 132240 120134 90.85% 94679
B013 151876 142585 93.88% 99025
B014 134619 126784 94.18% 95377
B016 135457 126507 93.39% 89407
B017 141682 131968 93.14% 89465
B018 111228 102382 92.05% 56981
B019 128532 120719 93.92% 76877
B020 128441 121957 94.95% 89618
B031 140941 132311 93.88% 97962
B033 142462 134554 94.45% 80548
B034 148854 140059 94.09% 106050
Total 1621752 1517411 93.54% 1066941illustrated the percentage of probiotics detected by
the proposed platform. Table 2 listed the quantities
(matched sequenced reads) of probiotics identified in
the samples in the case study. The top three identi-
fied probiotics in 12 samples are Lactococcus salivar-
ius, Streptococcus thermophilus, and Bifidobacterium
longum. Figure 1B and Table 3 listed the proportion
and quantities of pathogens, of which top three pathogens
are Escherichia coli, Salmonella enteric, and Haemophilus
influenza.
Table 4 listed the results of disease risk evaluations. It
showed that three diseases of two samples (B031 and
B034) had similar distributions in the control group.
The three diseases are obesity, colorectal cancer, and
constipation. Sample B031 had reached the significance
level with P-value 0.0333 and 0.0121 < 0.05 of distribu-
tion in constipation and colorectal cancer respectively
compared to 98 samples control group using binomial
test. Sample B034 had reached the significance level with
P-value 0.00257 and 0.0121 < 0.05 of distribution in
obesity and colorectal cancer. Evaluated by the associ-
ation of bacterial risk markers and disease, the results
suggested that these two samples had higher risk than
98 samples control group in constipation, colorectal
cancer, and obesity. Their enterotypes of gut probiotics
and pathogens may be one of risk factors which would
cause disease.
Reproducibility and accuracy evaluation of proposed
platform
Two replicated experiments of four samples were per-
formed to estimate the reproducibility of the proposed
platform. The results of repeated experiments were con-
sistent. The similarity between two repeated experiments
were calculated by using UniFrac [19]. Results of eachidentified Probiotics Pathogens
77.44% 60 0.07% 3509 3.86%
78.81% 3457 3.65% 20109 21.24%
69.45% 3452 3.49% 21341 21.55%
75.23% 611 0.64% 6665 6.99%
70.67% 49 0.05% 20870 23.34%
67.79% 1064 1.19% 8944 10.00%
55.66% 910 1.60% 11630 20.41%
63.68% 305 0.40% 2775 3.61%
73.48% 123 0.14% 3673 4.10%
74.04% 2129 2.17% 5194 5.30%
59.86% 229 0.28% 2725 3.38%
75.72% 9857 9.29% 15436 14.56%
70.31% 22246 2.09% 122871 11.52%
Figure 1 Relative abundance of probiotics and pathogenic bacteria from human gut of all samples. (A) The percentage of probiotics was
identified in the samples. (B) The proportion of pathogenic bacteria was identified in the samples in the case study.
Table 2 The quantities (matched sequenced reads) of probiotics identified in the samples in the case study
Probiotics B011 B012 B013 B014 B016 B017 B018 B019 B020 B031 B033 B034
Bacillus coagulans 0 81 6 1 2 0 3 0 1 0 9 1 104
Bifidobacterium adolescentis 4 3 1520 81 1 372 185 177 1 5 0 375 2724
Bifidobacterium animalis 0 101 37 3 1 16 32 1 1 0 0 50 242
Bifidobacterium bifidum 0 3 3 0 0 84 2 0 0 0 0 21 113
Bifidobacterium breve 0 1092 465 96 6 102 212 13 2 9 18 79 2094
*Bifidobacterium longum 3 1859 1092 198 27 256 439 34 5 15 55 238 4221
Lactobacillus brevis 0 0 0 0 0 0 1 0 0 0 0 10 11
Lactobacillus casei 0 10 1 1 0 0 0 0 0 1 0 0 13
Lactobacillus fermentum 0 0 0 0 1 0 0 4 0 1 0 28 34
Lactobacillus gasseri 0 0 0 1 1 0 0 0 0 0 0 77 79
Lactobacillus johnsonii 0 0 0 0 0 0 0 0 0 0 0 7 7
Lactobacillus paracasei 0 1 2 0 0 0 0 0 0 0 0 1 4
Lactobacillus plantarum 1 0 0 2 0 0 0 0 0 0 0 0 3
Lactobacillus reuteri 0 0 0 1 0 0 0 0 0 0 0 1 2
Lactobacillus rhamnosus 0 1 0 0 0 0 0 0 0 0 0 2 3
*Lactobacillus salivarius 2 1 2 8 1 5 3 1 3 11 2 6753 6792
Lactococcus lactis 2 0 0 6 1 0 2 0 0 16 1 10 38
*Streptococcus thermophilus 48 305 324 213 8 229 31 75 110 2071 144 2204 5762
60 3457 3452 611 49 1064 910 305 123 2129 229 9857
For each species, if the number of reads is 0 for all samples, that species was not shown.
*The leading three probiotics are Lactococcus salivarius, Streptococcus thermophilus and Bifidobacterium longum.
Chiu et al. Journal of Clinical Bioinformatics 2014, 4:1 Page 3 of 13
http://www.jclinbioinformatics.com/content/4/1/1
Table 3 The quantities (matched sequenced reads) of pathogens identified in the samples in the case study
Pathogens B011 B012 B013 B014 B016 B017 B018 B019 B020 B031 B033 B034
Bordetella pertussis 0 1 0 0 0 1 0 0 0 0 0 0 2
Brucella abortus 0 0 0 0 0 0 0 0 0 0 0 0 0
Brucella melitensis 0 0 0 0 0 0 0 0 0 0 0 0 0
Campylobacter jejuni 0 0 0 11 0 0 0 0 0 11 1 40 63
Clostridium botulinum 0 38 5048 4 5 2 1 361 153 1211 115 59 6997
Clostridium difficile 0 0 1 0 0 0 0 0 0 0 0 0 1
Clostridium perfringens 0 1 2 0 0 0 0 3 10 24 12 93 145
Corynebacterium diphtheriae 0 1 0 1 0 0 0 0 0 1 0 0 3
Enterococcus faecalis 57 13 1 4 8 4 0 20 5 19 6 38 175
Enterococcus faecium 41 8 2 6 5 2 1 22 3 13 1 32 136
*Escherichia coli 1744 8560 7900 3637 10651 4404 5691 1424 1733 210 165 4483 50602
*Haemophilus influenzae 2 1771 2 1055 8 49 1 171 15 1802 2322 4502 11700
Neisseria meningitidis 0 2 0 3 1 0 1 1 1 1 1 1 12
Pseudomonas aeruginosa 1 6 6 4 2 2 3 1 3 0 0 3 31
*Salmonella enterica 1570 9291 7978 1849 9864 4209 5726 622 1658 303 44 4495 47609
Shigella sonnei 41 243 239 32 308 122 192 8 41 1 1 98 1326
Staphylococcus aureus 0 0 0 0 0 0 0 0 1 0 0 0 1
Staphylococcus epidermidis 0 0 0 0 0 0 0 1 1 0 0 0 2
Streptococcus agalactiae 0 69 3 0 5 0 1 0 0 3 6 5 92
Streptococcus pneumoniae 46 26 9 16 1 36 3 46 25 272 5 154 639
Streptococcus pyogenes 7 76 149 14 10 112 9 94 23 417 45 1428 2384
Vibrio cholerae 0 3 0 0 0 1 1 0 1 0 1 0 7
Yersinia pestis 0 0 1 29 2 0 0 1 0 906 0 5 944
3509 20109 21341 6665 20870 8944 11630 2775 3673 5194 2725 15436
For each species, if the number of reads is 0 for all samples, that species was not shown.
*The leading three pathogens are Escherichia coli, Salmonella enterica and Haemophilus influenzae.
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other. The similarity of UniFrac distance of each sample
pair is higher than 0.96 (0.9617 for B014, 0.9872 for
B018, 0.9914 for B020, 0.9722 for B033). This implies
that the analysis results are reproducible.
Next, accuracy of the platform is evaluated by adding
Lactobacillus reuteri to a stool sample (B050). Sample
B050 contains 24,408 assigned taxons, and Lactobacillus
reuteri has no detected count. Whether the counts of
this species in positive control sample (B050S_L) are
elevated must be determined. Analysis results indicate
that 27,113 taxons are detected in sample B050S_L. In
fact, the detected counts of Lactobacillus reuteri in sam-
ple B050S_L are 1,430, and the percentage of Lactobacil-
lus reuteri markedly increases from 0% to 5%.
In short, our platform is accurate and reproducible in
terms of detecting the quantities of bacterial species of
the proposed platform. The results evaluate the accuracy
and feasibility of proposed platform in order to identify
probiotics and pathogens. While requiring only about
one day for detection, not limited in identifying certainbacteria, the proposed platform can detect and quantify
multiple bacteria simultaneously.
Discussion
Because of the constraint of costs and technical limita-
tions, 16S rRNA sequences obtained in most databases
are partial sequences. Many studies thus assign tax-
onomy by using partial 16S rRNA sequences. In our
probiotics and pathogens 16S rRNA sequence database,
17,964 sequences are collected from NCBI nucleotide
database, NCBI 16S microbial rRNA database, Green-
genes database, and SILVA. Our probiotics and patho-
gens 16S rRNA database contain less than 39% of 16S
rRNA sequences which are longer than 1400 bps. Only
9% of the sequences are close to full length.
This work extracts the V4 region from full length 16S
rRNA of microbiome in the human gut as a platform
application. Some 16S rRNA variable regions are more
dependable than other regions in assigning taxonomy
like V3 and V4 [20,21]; in addition, some 16S rRNA
variable regions are much conserved. The proportion
Table 4 The result of disease risk evaluations of 12 samples
Disease B011 B012 B013 B014 B016 B017 B018 B019 B020 B031 B033 B034
Constipation 2.67E-01 2.67E-01 2.67E-01 1.00E + 00 1.00E + 00 2.67E-01 1.00E + 00 1.00E + 00 2.67E-01 3.34E-02 2.67E-01 1.00E + 00
Obesity 1.34E-01 1.34E-01 1.00E + 00 1.34E-01 1.00E + 00 1.34E-01 1.34E-01 1.00E + 00 1.00E + 00 1.34E-01 1.00E + 00 2.57E-03
IBS 3.33E-01 7.06E-01 1.00E + 00 3.33E-01 1.00E + 00 3.33E-01 3.33E-01 1.00E + 00 1.10E-01 1.10E-01 7.06E-01 3.33E-01
Ulcerative colitis 9.30E-02 4.15E-01 1.00E + 00 4.15E-01 1.00E + 00 9.30E-02 4.15E-01 1.00E + 00 9.30E-02 1.00E + 00 1.00E + 00 1.00E + 00
Colorectal cancer 4.88E-01 2.59E-01 9.35E-01 7.47E-01 7.47E-01 7.47E-01 2.59E-01 4.88E-01 4.88E-01 1.22E-02 7.47E-01 1.22E-02
Atopic dermatitis 1.83E-01 1.00E + 00 1.00E + 00 1.00E + 00 1.00E + 00 1.83E-01 1.83E-01 1.00E + 00 1.00E + 00 1.00E + 00 1.00E + 00 1.83E-01
Allergic rhinitis 1.89E-01 1.00E + 00 1.00E + 00 1.00E + 00 1.00E + 00 1.89E-01 1.89E-01 1.89E-01 1.00E + 00 1.89E-01 1.00E + 00 1.89E-01
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diverse by using different 16S rRNA variable regions.
The proposed platform is also applicable to other 16S
rRNA variable regions for taxonomy assignment. Im-
portantly, a more appropriate region than others must
be selected to produce an outcome that is close to full
length 16S rRNA sequence.
This work further attempt is to collect common probio-
tics and pathogens from the literature. Although it may be
incomplete, recent advances in sequencing technology
make it possible to identify and define an increasing
number of bacteria, implying an obvious increase in the
number of identified probiotics and pathogens in the
future. Efforts are underway in our laboratory to update
the list of used probiotics and pathogens.
Previous studies [22-24] identified pathogen or pro-
biotic bacteria by using antibody, 16S rRNA gene micro-
arrays, fluorescence in situ hybridization (FISH), and
proteomic methods. In this work, the proposed platform
can detect various pathogens and probiotics based on
16S rRNA (rDNA) sequences of bacteria using NGS and
Bioinformatics method. An average of 126,451 reads was
acquired per sample in this work. It is doubt that the
sequencing depth is enough to detect a small amount of
probiotics and pathogens. Although increasing the cover-
age of sequencing can advance the sensitivity of detecting
probiotics and pathogens, the sequencing cost will in-
crease. It is important to work out an appropriate cover-
age of sequencing for detecting probiotics and pathogens.
The results of disease risk evaluations revealed that
most of 12 samples did not have resembled distributions
of bacteria markers with control group. Only two sam-
ples had reached the significance level of distributions.
The reason for the phenomenon may be the overlapped
bacteria markers between diseases. 28 markers are used
in colorectal cancer, and 17 markers are used in irritable
bowel syndrome. Six markers are overlapped. For sample
B031, the significant distributions in colorectal cancer
were partly contributed to the significance in irritable
bowel syndrome owing to the overlapped markers. Simi-
larly, two overlapped markers for sample B034 were in
colorectal cancer and obesity. In this kind of speculation,
the influence of colorectal cancer to irritable bowel syn-
drome would be six (overlapped markers of CC and IBS)
over seventeen (markers of IBS), and the influence of
colorectal cancer to obesity would be two (overlapped
markers of CC and obesity) over nine (markers of obes-
ity). In addition, the influence of colorectal cancer to
constipation and ulcerative colitis would be one over six
and two over ten, respectively.
In addition to that some bacteria markers in species
level are belong to the marker of genus level and spe-
cies level, both genus marker and species markers
may have associated with affecting the distributionsmutually. Continually, collecting more markers and
evaluating the distributions with markers in the same
level are required for constructing a global prediction
model in Taiwanese.
Conclusions
This work constructed a bacterial disease risk evaluation
model for seven diseases and developed a novel platform
by using NGS and Bioinformatics approach. Compared
with the traditional bacteria culture method, our pro-
posed platform can reduce experiment time. Besides, the
proportion of probiotics and pathogens (including
uncultivable pathogens) in the human body can be
detected rapidly with 16 s RNA database of probiotics
and pathogens. Furthermore, the proposed platform pro-
vides further insight into the cause of disease based on
the relation of probiotics, pathogens, and disease. For
instance, the type of antibiotics can be adjusted if the
pathogens of disease are identified from infected patients.
In addition, the proposed platform allows researchers to
determine whether the intake of probiotics impacts the
human body [25-29]. In the future, this preliminary study
will be continuously extended for more bacterial disease
markers. For more comprehensive applications, this work
will also collect bacteria from other parts of human body
as control group data. In fact, a detective method of how
the probiotics and pathogens inhabit human can provide
new insight for human health. It could improve diagnosis
and treatment method.
Methods
Figure 2 illustrates the bioinformatics system flow of the
proposed platform, which includes analysis pipeline of
NGS. The Figure 2 contains four parts: sequence quality
filtering, construction of bacteria sequence database,
taxonomy assignment, and disease risk model evaluation.
The detailed components in the proposed platform are
described below.
Sample collection
In this study, stool samples of 98 Taiwan volunteers
were gathered. The samples were collected by Sigma-
transwab (Medical Wire) into a tube with Liquid Amies
Transport Medium, and stored at 4°C until processing.
DNA extraction
In the case study, fresh faeces were obtained from partici-
pants. DNA was extracted directly on stool samples by
using a QIAamp DNA Stool Mini Kit (Qiagen). A swab
was vortexed vigorously and incubated at room tempe-
rature for 1 min. The sample was then transferred to
microcentrifuge tubes containing 560 μl Buffer ASL,
vortexed, and incubated at 37°C for 30 min. In addition,
the suspension was incubated at 95°C for 15 min,
Figure 2 System flow of bioinformatics analysis in the proposed platform. The proposed platform comprises the analysis pipeline of
NGS, construction of probiotics and pathogens database, bacterial disease risk model evaluation and the application of individualized bacteria
sequencing profile.
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pellet stool particles. Extraction was performed following
the protocol of the QIAamp DNA Stool Mini Kit. The
DNA was eluted with 50 μl Buffer AE, and centrifuged at
14,000 rpm for 1 min. Moreover, the DNA extract was
stored at−20°C until further analysis. Finally, DNA extrac-
tion was performed, depending on the sample collected.
Library construction and sequencing for V4 region of 16S
ribosomal DNA
The PCR primers, F515 (5′-GTGCCAGCMGCCGCGG
TAA-3′) and R806 (5′-GGACTACHVGGGTWTCTA
AT-3′), were designed to amplify the V4 domain of
bacterial 16S ribosomal DNA as described previously
[30]. PCR amplification was performed in a 50 μl
reaction volume containing 25 μl 2X Taq Master Mix
(Thermo Scientific), 0.2 μM of each forward and reverse
primer, and 20 ng DNA template. The reaction condi-
tions consisted of an initial 95°C for 5 min, followed by
30 cycles of 95°C for 30 sec, 54°C for 1 min, and 72°C
for 1 min, as well as a final extension of 72°C for 5 min.
Next, amplified products were checked by 2% agarose
gel electrophoresis and ethidium bromide staining.
Amplicons were purified using the AMPure XP PCR
Purification Kit (Agencourt), and quantified using Qubit
dsDNA HS Assay Kit (Qubit) on Qubit 2.0 Fluorometer
(Qubit)–all according to respective manufacturer in-
structions. For V4 library preparation, Illumina adapters
were attached to the amplicons using the IlluminaTruSeq DNA Sample Preparation v2 Kit. Purified librar-
ies were applied for cluster generation and sequencing
on the MiSeq system. The raw sequence files are avail-
able for download at http://clinic.mbc.nctu.edu.tw/.
16S rRNA (rDNA) sequence data quality filtering
The raw fastq files obtained by Illumina sequencing ma-
chine were quality-filtered using the FASTX-Toolkita.
The paired-end 150 bp reads were performed using the
minimum acceptable phred quality score of 20, as well
as the 70% of bases that must exceed 20 phred quality
score. Sequence shorter than 100 nucleotides would be
omitted after quality trimming from reads tail. Notably,
reads containing ambiguous characters were discarded.
Construction of probiotics and pathogens database
The list of probiotics and pathogens were obtained from
literatures or the claims of official departments. Additional
file 1: Table S1 lists species of probiotics which were
adapted from both literatures [7,9] and the claims of
official departments, such as Taiwan Food and Drug
Administration [31] and Health Canada [32]. 99 bacterial
pathogens were collected from literature [25,26,33-42] and
Taiwan Food and Drug Administration [31] (Additional
file 1: Table S2).
The 16S rRNA sequences of probiotics and pathogens
used for taxonomy mapping were retrieved from the
NCBI nucleotide database, NCBI 16S microbial rRNA
database, Greengenes database [43] and SILVA [44].
Table 5 Disease-related biomarkers of seven diseases
Disease Marker Correlation Lower bound Upper bound Case Control Pubmed ID
Constipation Escherichia coli - 2.86E-03 1.52E-01 35 35 20039451
Roseburia - 1.41E-03 4.61E-02 14 12 22315951
Lactobacillus - 6.10E-05 9.45E-03 14 12 22315951
Bifidobacterium - 5.39E-05 1.73E-02 14 12 22315951
Enterobacteriaceae + 1.00E-02 4.26E-01 14 12 22315951
Ruminococcus bromii + 1.16E-05 4.98E-03 8 15 20014457
Obesity Prevotella - 2.46E-03 5.36E-01 23 13 20876719
Bifidobacterium - 5.39E-05 1.73E-02 33 30 19498350
Lachnospiraceae - 3.11E-03 6.74E-02 3 3 19164560
Verrucomicrobiae - 1.43E-05 1.78E-02 3 3 19164560
Akkermansia - 1.43E-05 1.78E-02 3 3 19164560
Faecalibacterium prausnitzii + 7.70E-04 2.15E-02 15 13 19849869
Lactobacillus + 6.10E-05 9.45E-03 20 20 19774074
Coriobacteriaceae + 3.26E-05 4.72E-03 3 3 19164560
Erysipelotrichaceae + 1.35E-04 6.64E-03 3 3 19164560
Ulcerative colitis Bacteroides uniformis - 7.63E-04 5.44E-02 13 22 21073731
Bacteroides vulgatus - 1.55E-03 4.21E-02 13 22 21073731
Parabacteroides distasonis - 2.22E-05 1.68E-03 13 22 21073731
Faecalibacterium prausnitzii - 7.70E-04 2.15E-02 13 27 19235886
Firmicutes - 9.18E-02 4.50E-01 13 27 19235886
Clostridium - 2.48E-03 6.03E-02 31 30 21253779
Clostridium leptum - 9.65E-06 1.05E-03 13 27 19235886
Bifidobacterium - 5.39E-05 1.73E-02 13 27 19235886
Bacteroides ovatus - 2.04E-04 1.81E-02 13 22 21073731
Escherichia coli + 2.86E-03 1.52E-01 9 9 16954244
Atopic dermatitis Lactobacillus - 6.10E-05 9.45E-03 68 256 17604093
Bifidobacteriales - 8.09E-05 1.84E-02 7 27 20626364
Bacteroides + 6.56E-02 6.37E-01 68 256 17604093
Clostridium perfringens + 0.00E + 00 1.06E-04 15 15 21963389
Colorectal cancer Bacteroides uniformis - 7.63E-04 5.44E-02 46 56 21850056
Roseburia - 1.41E-03 4.61E-02 46 56 21850056
Fusobacterium - 3.32E-05 2.64E-02 50 38 7574628
Eubacterium - 1.36E-03 7.92E-02 46 56 21850056
Coprococcus - 1.91E-05 2.89E-03 21 23 20740058
Collinsella aerofaciens - 2.39E-05 2.09E-03 50 38 7574628
Alistipes - 4.07E-04 2.60E-02 46 56 21850056
Sutterellaceae - 9.39E-04 4.85E-02 46 56 21850056
Escherichia + 3.05E-03 1.85E-01 46 56 21850056
Shigella + 1.51E-03 8.84E-02 46 56 21850056
Bacteroides fragilis + 7.22E-06 1.92E-02 46 56 21850056
Porphyromonas + 0.00E + 00 1.59E-05 46 56 21850056
Faecalibacterium prausnitzii + 7.70E-04 2.15E-02 50 38 7574628
Ruminococcus albus + 0.00E + 00 4.95E-04 50 38 7574628
Streptococcus + 1.12E-04 6.83E-03 46 56 21850056
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Table 5 Disease-related biomarkers of seven diseases (Continued)
Blautia hansenii + 0.00E + 00 6.77E-05 50 38 7574628
Enterococcus + 0.00E + 00 1.19E-04 46 56 21850056
Bifidobacterium angulatum + 0.00E + 00 2.60E-05 50 38 7574628
Blautia producta + 0.00E + 00 1.10E-04 50 38 7574628
Ruminococcus gnavus + 1.04E-05 2.64E-03 50 38 7574628
Eubacterium eligens + 7.09E-05 2.05E-02 50 38 7574628
Eubacterium rectale + 8.13E-05 1.34E-02 50 38 7574628
Bacteroides stercoris + 4.87E-05 2.94E-02 50 38 7574628
Enterobacteriales + 1.00E-02 4.26E-01 10 10 21647227
Erysipelotrichaceae + 1.35E-04 6.64E-03 50 38 7574628
Dorea + 5.67E-05 6.08E-03 21 23 20740058
Bifidobacterium longum + 1.56E-05 3.60E-03 50 38 7574628
Faecalibacterium + 1.66E-03 6.79E-02 21 23 20740058
Irritable bowel syndrome Bacteroides uniformis - 7.63E-04 5.44E-02 11 22 21073731
Bacteroides vulgatus - 1.55E-03 4.21E-02 11 22 21073731
Parabacteroides distasonis - 2.22E-05 1.68E-03 11 22 21073731
Faecalibacterium prausnitzii - 7.70E-04 2.15E-02 23 23 22339879
Bacteroidetes - 2.87E-01 7.95E-01 62 46 21820992
Bifidobacterium - 5.39E-05 1.73E-02 62 46 21820992
Bacteroides ovatus - 2.04E-04 1.81E-02 11 22 21073731
Faecalibacterium - 1.66E-03 6.79E-02 62 46 21820992
Escherichia coli + 2.86E-03 1.52E-01 14 18 22356587
Haemophilus + 1.02E-05 1.69E-03 22 22 21741921
Fusobacterium + 3.32E-05 2.64E-02 23 23 22339879
Gammaproteobacteria + 1.75E-02 4.69E-01 22 22 21741921
Ruminococcus + 1.22E-03 4.08E-02 62 46 21820992
Enterococcus + 0.00E + 00 1.19E-04 23 23 22339879
Veillonella + 1.12E-05 7.82E-03 26 26 19903265
Lactobacillaceae + 6.10E-05 9.45E-03 23 23 22339879
Dorea + 5.67E-05 6.08E-03 62 46 21820992
Allergic rhinitis Lactobacillus - 6.10E-05 9.45E-03 12 12 19714856
Bifidobacterium - 5.39E-05 1.73E-02 67 20 101
Bacteroides fragilis + 7.22E-06 1.92E-02 22 22 17893165
Faecalibacterium prausnitzii + 7.70E-04 2.15E-02 22 22 17893165
The associations between bacterium and disease are majorly collected from case–control studies which the quantities of bacterium are obtained from deep
sequencing data. The proportion of 78 bacteria from control group was applied as risk markers (constipation: 6, obesity: 9, IBS: 17, UC: 10, CC: 28, AD: 4, AR: 4) to
predict disease risk to seven diseases in this study.
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sequences which used the same species classification
and removed redundant sequences. Additionally, we also
removed the unique sequence from only one research
support with 3% similarity which shared the same species
classification with other sequence.
Taxonomy mapping
To generate taxonomy assignments, the proposed platform
invoked a modified Smith-Waterman algorithm frommiRExpress [45], which can compare pairs of sequences in
parallel, for mapping reads to taxons. miRExpress was
designed for identifying the best similarity between sequen-
cing reads and miRNA precursor sequences. In our model,
it was modified for identifying multiple hits of 16S rRNA
sequence mapping results with similarity threshold 0.97. In
order to reduce the storage space of output, the SAM
format [46] was used to replace the original miRExpress
output format for storing alignment results. Furthermore,
two kinds of output format were designed. One format
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The other one records which taxons could be assigned
based on sequencing reads. These two kinds of output
could support the important information for assigning
sequencing reads to suitable taxon. miRExpress was origin-
ally designed for dealing with single-end sequencing data.
Therefore, the additional program was added for process-
ing paired-end sequencing data. In this part, both end
sequencing reads need to be assigned to the same taxon. If
paired-end sequencing reads were mapped to different
taxons, this paired sequence would be dropped. The
probiotics and pathogens 16S rRNA sequence from our
database were built in FASTA format. Following quality
filtering, all paired-end sequences were aligned to the pro-
biotics and pathogens database with whole read aligned
from one end to the other end. Reads were then truncated
with an identity lower than 97%, according to previous
research in order to achieve a better compromise between
sequences from PCR sequencing errors and taxonomic
relatedness [27].
The construction of Bacterial disease risk evaluation
model (BDREM)
To study the associations between bacteria and diseases,
we collected related information from literatures. We con-
cerned bacteria that are associated with seven diseases:Figure 3 An example for evaluating the risk of obesity by using bacte
upper proportion bound of 9 markers from 98 control samples to define ri
binomial test.constipation [28,47,48], obesity [29,49-52], irritable
bowel syndrome (IBS) [28,53-58], ulcerative colitis
(UC) [53,59-61], colon cancer (CC) [62-64], Atopic
Dermatitis (AD) and Allergic rhinitis (AR), were col-
lected positive correlation and negative correlation
data, and the individual risk of disease was evaluated.
The association data were majorly collected from
case–control studies which the quantities of bacteria
were obtained from NGS data, and few well-known
bacteria validated by multiple studies through cultural
experiments were also included. We further eliminated
some conflicted data with both positive and negative
correlation between bacteria and disease in different
studies.
Health Asians stool samples of 98 Taiwan volunteers
were gathered. Following deep sequencing and sequen-
cing data processing, the proportion of 78 bacteria from
control group was applied as risk markers (constipation:
6, obesity: 9, IBS: 17, UC: 10, CC: 28, AD: 4, AR: 4) to
predict disease risk to seven diseases in this study
(Table 5).
The mathematical formula of BDREM in this study
was developed as the following steps. Let λ be a N × S
matrix, where N is the number of markers selected in
the prediction model of constipation and S is the num-
ber of health subjects in 7 prediction models. Ti wasrial disease risk evaluation model. The model used lower and
sk markers of these two samples (B034 and B031) following by using
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row of λ [65]. Ti is a threshold to distinguish λij from
normal proportion level to abnormal (fail to success in
one trail of binomial distribution). Smaller notch was
selected to Ti when each marker was recorded as a
negative association to the disease, and a success trail
was identified when λij is smaller than Ti. On the oppos-
ite, larger notch was selected when association was
positive, and a success trail was identified when λij is
larger than Ti.
Ti ¼










Let Pj be the probability of successful trails in the j
th
column of λ. The meaning of Pj is the personal probabil-
ity that abnormal proportion level happened.
Pj ¼ # success trails in the jth column of λ:N
Let Ph be the mean of Pj. It represents how frequent
the abnormal proportion level happened to all Pj in
average, regarded as the hypothesized probability of





Assume Pj obey a binomial distribution, and let Ph be
the hypothesized probability (0.05051 for constipation,
0.07239 for obesity, 0.06952 for IBS, 0.05227 for UC,
0.09280 for CC, 0.04924 for AD, 0.05114 for AR). A bi-
nomial test was used to Pj and Ph. Alpha = 0.05 was
choose to judge if a subject is significantly differently
from the others in λ.
Figure 3 illustrated an example for evaluating the risk
of obesity of B034 and B031. The model used lower and
upper proportion bound of 9 markers from 98 control
samples to define risk markers of these two samples fol-
lowing by using binomial test. Four markers of B034 ex-
ceed the lower bound and upper bound of obesity. The
binomial test P-Value of B034 is 2.572e-03 < 0.05, Since
P-Value < = hypothesized probability 0.07239, this case is
specifically associated (significantly) with disease than
random chance. There are two markers of B031 ex-
ceed lower bound of obesity. The P-Value of B031 is
0.1344 > 0.05, the case is no more associated with
disease than random chance. As the results, we can
assume that B034 had higher probability to cause
Obesity.Endnote
ahttp://hannonlab.cshl.edu/fastx_toolkit/index.html.Additional file
Additional file 1: The list of probiotics and pathogens were
obtained from literatures or the claims of official departments:
Table S1. The reference list of probiotics. Table S2. The reference list of
pathogens.
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